Enhanced tuberculosis case detection among substitution treatment patients: a randomized controlled trial

Kristi Rüütel, Helle-Mai Loit, Tiiu Sepp, Kai Kliiman, Louise-Anne McNutt, Anneli Uusküla, Kristi Rüütel, Helle-Mai Loit, Tiiu Sepp, Kai Kliiman, Louise-Anne McNutt, Anneli Uusküla

Abstract

Background: Historically, HIV, TB (tuberculosis) and illegal drug treatment services in Estonia have been developed as vertical structures. Related health care services are often provided by different health care institutions and in different locations. This may present obstacles for vulnerable groups, such as injecting drug users (IDU), to access the needed services. We conducted a small scale randomized controlled trial to evaluate a case management intervention aimed at increasing TB screening and treatment entry among IDUs referred from a methadone drug treatment program in Jõhvi, North-Eastern Estonia.

Findings: Of the 189 potential subjects, 112 (59%) participated. HIV prevalence was 86% (n = 96) and 7.4% (n = 8) of participants were interferon gamma release assay (IGRA) positive (6.5% were both HIV and IGRA-positive, n = 7). Overall, 44% of participants (n = 49) attended TB clinic, 17 (30%) from control group and 32 (57%) from case management group (p = 0.004). None of the participants were diagnosed with TB. In a multivariate model, those randomized to case management group were more likely to access TB screening services.

Conclusions: These findings demonstrate the urgent need for scaling up TB screening among IDUs and the value of more active approach in referring substitution treatment patients to TB services.

Trial registration: ClinicalTrials.gov: NCT01290081.

References

    1. Perlman DC, Salomon N, Perkins MP, Yancovitz S, Paone D, Des Jarlais DC. Tuberculosis in drug users. Clin Infect Dis. 1995;21:1253–1264. doi: 10.1093/clinids/21.5.1253.
    1. Friedland G. Infectious disease comorbidities adversely affecting substance users with HIV: hepatitis C and tuberculosis. J Acquir Immune Defic Syndr. 2010;55:S37–S42.
    1. Van Deutekom H, Warris-Versteegent AA, Krijnen P, Posternat CA, van Wijngaardent JK, van den Hock JAR, Coutinho RA. The HIV epidemic and its effect on the tuberculosis situation in the Netherlands. Tuberc Lung Dis. 1993;74:159–162. doi: 10.1016/0962-8479(93)90004-H.
    1. Estonian National Tuberculosis Registry.
    1. Estonian Statistical Database.
    1. European Centre for Disease Prevention and Control/WHO Regional Office for Europe. HIV/AIDS surveillance in Europe 2007. Stockholm; European Centre for Disease Prevention and Control;
    1. Uusküla A, Rajaleid K, Talu A, Abel K, Rüütel K, Hay G. Estimating injection drug use prevalence using state wide administrative data sources: Estonia, 2004. Addict Res Theory. 2007;15:411–424. doi: 10.1080/16066350701417533.
    1. Lõhmus L, Rüütel K, Abel-Ollo K, Loit HM, Talu A, Uusküla A. HIV-nakkuse ning teiste infektsioonide ja riskikäitumise levimus süstivate narkomaanide seas Tallinnas ja Kohtla-Järvel, 2007. Tallinn, Estonia; 2008. HIV and other infections and related risk behaviours among injecting drug users, 2007.
    1. Rüütel K, Karnite A, Brokere I, Talu A, Abel-Ollo K, Kirvelaite G, Uusküla A. Prevalence of latent tuberculosis and risk factors among injecting drug users in Estonia and Latvia. 5th European Conference on Clinical and Social Research on AIDS and Drugs: 28-30 April 2009; Vilnius.
    1. Sylla L, Bruce RD, Kamarulzaman A, Altice FL. Integration and co-location of HIV/AIDS, tuberculosis and drug treatment services. Int J Drug Policy. 2007;18:306–312. doi: 10.1016/j.drugpo.2007.03.001.
    1. El Sadr W, Medard F, Barthaud V. Directly observed therapy for tuberculosis: the Harlem Hospital experience, 1993. Am J Public Health. 1996;86:1146–1149. doi: 10.2105/AJPH.86.8_Pt_1.1146.
    1. Friedmann PD, D'Aunno TA, Jin L, Alexander JA. Medical and psychosocial services in drug abuse treatment: do stronger linkages promote client utilization? Health Services Res. 2000;35:443–465.
    1. Strathdee SA, Ricketts EP, Huettner S, Cornelius L, Bishai D, Havens JR, Beilenson P, Rapp C, Lloyd JL, Latkin CA. Facilitating entry into drug treatment among injection drug users referred from a needle exchange program: Results from a community-based behavioral intervention trial. Drug Alcohol Depend. 2000;83:225–232.
    1. Des Jarlais DC, Perlis TE, Stimson GV, Poznyak V. WHO Phase II Drug Injection Collaborative Study Group. Using standardized methods for research on HIV and injecting drug use in developing/transitional countries: case study from the WHO Drug Injection Study Phase II. BMC Public Health. 2006;6:54. doi: 10.1186/1471-2458-6-54.
    1. Salomon N, Perlman DC, Freidmann P, Perkins MP, Ziluck V, Des Jarlais DC, Paone D. Knowledge of tuberculosis among drug users relationship to return rates for tuberculosis screening at a syringe exchange. J Subst Abuse Treat. 1999;3:229–235.
    1. UNAIDS/WHO Working Group on Global HIV/AIDS and STI Surveillance. Guidelines for second generation HIV surveillance: The next decade. World Health Organization and Joint United Nations Programme on HIV/AIDS; 2000.
    1. Wolfe H, Marmor M, Maslansky R, Nichols S, Simberkoff M, Des Jarlais DC, Moss A. Tuberculosis knowledge among New York City injection drug users. Am J Public Health. 1995;85:985–988. doi: 10.2105/AJPH.85.7.985.
    1. Cellestis. QuantiFERON®-TB Gold In-Tube assay. Test principle.
    1. Centers for Diseases Control and Prevention. Updated guidelines for using interferon gamma release assays to detect Mycobacterium tuberculosis infection -- United States, 2010. MMWR. 2010;59:1–25.
    1. Estonian Health Board: Vaktsineerimine [Vaccinations]
    1. Vink K. Tuberkuloosi diagnostika, ravi ja ravi jälgimise juhised. Tartu, Estonia; 2004. Guidelines for diagnosis, treatment and follow-up of tuberculosis.
    1. Durante AJ, Selwyn PA, O'Connor PG. Risk factors for and knowledge of Mycobacterium tuberculosis infection among drug users in substance abuse treatment. Addiction. 1998;93:1393–1401. doi: 10.1046/j.1360-0443.1998.939139310.x.
    1. Estrada AL. Epidemiology of HIV/AIDS, hepatitis B, hepatitis C, and tuberculosis among minority injection drug users. Public Health Rep. 2002;117:S126–S134.
    1. Selwyn PA, Hartel D, Lewis VA, Schoenbaum EE, Vermund SH, Klein RS, Walker AT, Friedland GH. A prospective study of the risk of tuberculosis among intravenous drug users with human immunodeticiency virus infection. New Engl J Med. 1989;320:545–550. doi: 10.1056/NEJM198903023200901.
    1. Malotte CK, Rhodes F, Mais KE. Tuberculosis screening and compliance with return for skin test reading among active drug users. Am J Public Health. 1998;88:792–796. doi: 10.2105/AJPH.88.5.792.
    1. Kliiman K, Centis R, Migliori GB, Floyd K, Hollo V, Danilovits M, Vink K, Nathanson E. Evaluation of DOTS-Plus in Estonia. Int J Tuberc Lung Dis. 2005;11:133s.
    1. Kliiman K, Altraja A. Predictors of poor treatment outcome in multi- and extensively drug-resistant pulmonary TB. Eur Respir J. 2009;33:1085–1094. doi: 10.1183/09031936.00155708.

Source: PubMed

Sponsors and Collaborators

Medical Conditions

Drug Interventions

3
Subscribe